• M344 Histone Deacetylase Inhibitor: Applied Workflows & Opti

  2026-05-09

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor, enabling precise epigenetic modulation in cancer and viral latency research. This guide distills experimental protocols, troubleshooting strategies, and evidence-based insights to help researchers leverage M344 for advanced oncology and HIV-1 latency applications.

• Tubastatin A Limits Myocardial Injury Post-Cardiac Arrest in

  2026-05-08

  A recent experimental study demonstrates that Tubastatin A, a potent and selective HDAC6 inhibitor, alleviates myocardial damage following cardiac arrest and resuscitation in a porcine model. The findings highlight the compound’s capacity to reduce pyroptosis and necroptosis in cardiac tissue, offering mechanistic insight for future translational research.

• Hexa His Tag Peptide: Engineering Next-Generation Protein Pu

  2026-05-08

  Discover how the Hexa His tag peptide enables precision control in 6X His-tagged protein purification and interaction analysis. This article uniquely explores the interplay between recombinant protein metal binding and advanced assay design, with actionable insights for molecular biologists.

• CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition

  2026-05-07

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro research on cell cycle arrest and apoptosis in cancer models. It should not be used for diagnostic or clinical applications or outside established cell-based assay workflows.

• JC-1 Fluorescent Probe: Precision Mitochondrial Membrane Ass

  2026-05-07

  JC-1 stands as the gold standard for mitochondrial membrane potential assays, enabling precise detection of mitochondrial integrity and apoptosis in live cells. This guide details stepwise workflows, experimental enhancements, and troubleshooting strategies to maximize JC-1’s reliability in advanced cellular bioenergetics and dysfunction research.

• NADH (Reduced Nicotinamide Adenine Dinucleotide) in Mitochon

  2026-05-06

  NADH (reduced nicotinamide adenine dinucleotide) is a key coenzyme for cellular energy metabolism and redox balance. Its quantifiable role as an electron donor in mitochondrial electron transport chain research enables precise modeling of metabolic and disease processes. APExBIO’s NADH (CAS No. 58-68-4) is rigorously characterized for research reproducibility.

• Apicidin: Precision HDAC Inhibition and Assay Design Insight

  2026-05-06

  Explore Apicidin, a selective histone deacetylase inhibitor, in-depth. This article provides advanced guidance for assay optimization and addresses nuanced biological effects, setting it apart from existing discussions.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-05-05

  CUDC-907 provides researchers with a dual PI3K and HDAC inhibitor suitable for mechanistic studies in cancer cell models. It is designed for in vitro workflows requiring simultaneous inhibition of PI3K/AKT and HDAC signaling, but should not be used for clinical, diagnostic, or therapeutic purposes.

• TAI-1 Hec1 Inhibitor: Applied Workflows in Cancer Research

  2026-05-05

  TAI-1, a first-in-class Hec1 inhibitor from APExBIO, empowers cancer researchers with robust, high-sensitivity assays and unprecedented protocol flexibility. Learn how to harness its mechanistic selectivity, troubleshoot experimental bottlenecks, and align with breakthroughs in tumor suppressor biology.

• SIRT1/2 Inhibitor IV (cambinol): CNS and Cancer Protocols

  2026-05-04

  SIRT1/2 Inhibitor IV (cambinol) stands out for its dual role in probing tumorigenesis and central nervous system repair by precisely targeting SIRT1/2-driven metabolic-epigenetic pathways. This deep-dive translates recent breakthroughs in non-histone lactylation into actionable workflows, with stepwise troubleshooting and protocol optimization for both in vitro and in vivo research.

• Valemetostat in Relapsed/Refractory NHL: Phase 1 Clinical In

  2026-05-04

  This first-in-human, multicentre phase 1 trial demonstrates the safety and preliminary efficacy of Valemetostat (DS-3201), a dual EZH1/EZH2 inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. The findings highlight meaningful clinical activity and propose a recommended phase 2 dose, shaping the landscape of epigenetic cancer therapy for lymphoid malignancies.

• I-BET-762: Precision BET Inhibition and Ferroptosis Control

  2026-05-03

  Explore how I-BET-762, a potent BET inhibitor, uniquely modulates ferroptosis and gene regulation in cancer models. This in-depth analysis reveals practical assay strategies and mechanistic insights not covered by standard reviews.

• M344: Histone Deacetylase Inhibitor for Cancer & HIV Models

  2026-05-02

  M344 stands out as a potent, cell-permeable histone deacetylase inhibitor, enabling precise modulation of chromatin structure and gene expression in cancer and HIV latency research. This article offers actionable protocols, troubleshooting strategies, and comparative insights for researchers seeking robust, reproducible results with M344 from APExBIO.

• Strategic mRNA Reporting: Bridging Mechanism and Translation

  2026-05-01

  This thought-leadership article for translational researchers explores how dual-labeled, Cap1-capped, 5-moUTP-modified mRNAs—exemplified by APExBIO's EZ Cap™ Cy5 Firefly Luciferase mRNA—are redefining experimental rigor and translational relevance in gene delivery, tracking, and imaging. Drawing upon recent advances in mucus-penetrating nanoparticles and referencing competitive literature, we provide mechanistic insights and actionable protocol guidance for maximizing reporter assay fidelity, optimizing mRNA delivery, and suppressing innate immune activation. This piece goes beyond standard product descriptions by offering a strategic roadmap for researchers navigating the evolving landscape of mRNA-based therapeutics and vaccines.

• Dehydroepiandrosterone (DHEA): Applied Workflows in Neuropro

  2026-05-01

  Dehydroepiandrosterone (DHEA) is a versatile neuroprotection agent and apoptosis inhibitor with unique applications in both neural stem cell and ovarian granulosa cell assays. This article translates cutting-edge research and validated protocols into practical steps for reproducible, high-impact experimental outcomes.

16667 records 1/1112 page Next 12345 下5页 Last page